NASDAQ:HOOK

Hookipa Pharma Stock Forecast, Price & News

$11.00

-0.50 (-4.35 %)

(As of 12/2/2020 03:59 PM ET)

Add

Compare

Today's Range

$10.89

Now: $11.00▼

$11.43

50-Day Range

$9.32

MA: $10.39▼

$11.60

52-Week Range

$5.80

Now: $11.00▼

$14.37

Volume3,303 shs

Average Volume69,383 shs

Market Capitalization$240.36 million

P/E RatioN/A

Dividend YieldN/A

Beta1.02

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

3.5 Analyst's Opinion

Consensus Rating
Hookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.20, Hookipa Pharma has a forecasted upside of 82.6% from its current price of $11.06.
Amount of Analyst Coverage
Hookipa Pharma has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Hookipa Pharma has received 50 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hookipa Pharma has received 44 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hookipa Pharma has received 53.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote “Outperform” if you believe HOOK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Hookipa Pharma does not currently pay a dividend.
Dividend Growth
Hookipa Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hookipa Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,000.00 in company stock.
Percentage Held by Insiders
Only 4.02% of the stock of Hookipa Pharma is held by insiders.
Percentage Held by Institutions
Only 34.02% of the stock of Hookipa Pharma is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Hookipa Pharma are expected to decrease in the coming year, from ($1.84) to ($2.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hookipa Pharma is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hookipa Pharma is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hookipa Pharma has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.24 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HOOK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.hookipapharma.com

Phone431-890-6360

Employees56

Debt

Debt-to-Equity Ratio0.05

Current Ratio5.65

Quick Ratio5.65

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$11.94 million

Price / Sales20.13

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.22 per share

Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)($2.41)

Net Income$-43,040,000.00

Net Margins-232.00%

Return on Equity-39.58%

Return on Assets-31.33%

Miscellaneous

Outstanding Shares21,851,000

Market Cap$240.36 million

Next Earnings Date3/18/2021 (Estimated)

OptionableNot Optionable

$11.00

-0.50 (-4.35 %)

(As of 12/2/2020 03:59 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.

Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

How has Hookipa Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HOOK stock has increased by 20.0% and is now trading at $11.10.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Hookipa Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Hookipa Pharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Hookipa Pharma?

Wall Street analysts have given Hookipa Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hookipa Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Hookipa Pharma.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.11. Hookipa Pharma had a negative net margin of 232.00% and a negative return on equity of 39.58%.
View Hookipa Pharma's earnings history.

What price target have analysts set for HOOK?

5 brokers have issued twelve-month price targets for Hookipa Pharma's shares. Their forecasts range from $16.00 to $25.00. On average, they expect Hookipa Pharma's share price to reach $20.20 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price.
View analysts' price targets for Hookipa Pharma.

Who are some of Hookipa Pharma's key competitors?

Some companies that are related to Hookipa Pharma include Akero Therapeutics (AKRO), Arvinas (ARVN), Morphic (MORF), Frequency Therapeutics (FREQ), Syndax Pharmaceuticals (SNDX), Vectura Group (VEGPF), Provention Bio (PRVB), Protagonist Therapeutics (PTGX), Tocagen (TOCA), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Zafgen (ZFGN), Enanta Pharmaceuticals (ENTA), DiaMedica Therapeutics (DMCAF) and Esperion Therapeutics (ESPR).
View all competitors.

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the following people:

Mr. Joern Aldag, Pres, CEO & Director (Age 60)
Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
Dr. Reinhard Kandera, CFO & Director (Age 50)
Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.86%), State Street Corp (0.92%), Samsara BioCapital LLC (0.53%), Charles Schwab Investment Management Inc. (0.15%), Squarepoint Ops LLC (0.06%) and Morgan Stanley (0.05%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends for Hookipa Pharma.

Which institutional investors are selling Hookipa Pharma stock?

HOOK stock was sold by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Squarepoint Ops LLC, Morgan Stanley, and New York State Common Retirement Fund. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky, Klaus Orlinger, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma.

Which institutional investors are buying Hookipa Pharma stock?

HOOK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Charles Schwab Investment Management Inc., and BNP Paribas Arbitrage SA. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma.

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $11.10.

How big of a company is Hookipa Pharma?

Hookipa Pharma has a market capitalization of $242.55 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is www.hookipapharma.com.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings